Opipramol

Opipramol
Clinical data
Trade names	Insidon, Pramolan, others
Other names	G-33040; RP-8307
AHFS/Drugs.com	International Drug Names
Routes of; administration	By mouth
ATC code	N06AA05 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances); In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	94%
Protein binding	91%
Metabolism	CYP2D6-mediated
Elimination half-life	6–11 hours
Excretion	Urine (70%), feces (10%)
Identifiers
	IUPAC name 4-[3-(5H-dibenz[b,f]azepin- 5-yl)propyl]-1-piperazinethanol;
CAS Number	315-72-0 ; 909-39-7 (dihydrochloride);
PubChem CID	9417;
ChemSpider	9046 ;
UNII	D23ZXO613C;
KEGG	D08297 ;
ChEMBL	ChEMBL370753 ;
CompTox Dashboard (EPA)	DTXSID3023394 ;
ECHA InfoCard	100.005.687
Chemical and physical data
Formula	C23H29N3O
Molar mass	363.505 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OCCN1CCN(CC1)CCCN4c2ccccc2\C=C/c3ccccc34;
	InChI InChI=1S/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2 ; Key:YNZFUWZUGRBMHL-UHFFFAOYSA-N ;
	(what is this?) (verify)

Opipramol, sold under the brand name Insidon among others, is an anxiolytic and tricyclic antidepressant that is used throughout Europe. Despite chemically being a tricyclic dibenzazepine (iminostilbene) derivative similar to imipramine, opipramol is not a monoamine reuptake inhibitor like most other tricyclic antidepressants, and instead acts primarily as a sigma-1 receptor agonist. It was developed by Schindler and Blattner in 1961.